Twist Bioscience Corporation (TWST)

NASDAQ: TWST · IEX Real-Time Price · USD
38.20
-0.42 (-1.09%)
At close: Feb 23, 2024, 4:00 PM
38.40
+0.20 (0.52%)
After-hours: Feb 23, 2024, 5:45 PM EST

Company Description

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products.

The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution.

In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses.

Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody.

The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Twist Bioscience Corporation
Twist Bioscience logo
Country United States
Founded 2013
IPO Date Oct 31, 2018
Industry Diagnostics & Research
Sector Healthcare
Employees 919
CEO Dr. Emily Marine Leproust Ph.D.

Contact Details

Address:
681 Gateway Blvd.
South San Francisco, California 94080
United States
Phone 800-719-0671
Website twistbioscience.com

Stock Details

Ticker Symbol TWST
Exchange NASDAQ
Fiscal Year October - September
Reporting Currency USD
CIK Code 0001581280
CUSIP Number 90184D100
ISIN Number US90184D1000
Employer ID 46-2058888
SIC Code 2836

Key Executives

Name Position
Dr. Emily Marine Leproust Ph.D. Co-Founder, Chairman and Chief Executive Officer
Dr. Patrick John Finn Ph.D. President and Chief Operating Officer
Paula Green Senior Vice President of Human Resources
Dr. William Charles Banyai Ph.D. Senior Vice President of Advanced Development, GM of Data Storage and Director
Adam Laponis Chief Financial Officer
Robert F. Werner Vice President and Chief Accounting Officer
Siyuan Chen Chief Technology Officer
Dr. Aaron K. Sato Ph.D. Chief Scientific Officer
Chet Gandhi Chief Information Officer
Dennis Cho Senior Vice President, General Counsel, Secretary and Chief Ethics and Compliance Officer

Latest SEC Filings

Date Type Title
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 12, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 12, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 8, 2024 144 Filing
Feb 7, 2024 8-K Current Report
Feb 5, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 2, 2024 10-Q Quarterly Report
Feb 2, 2024 8-K Current Report